CA3044735C - Formations de cannabinoides hydrosolubles comprenant une enzyme - Google Patents

Formations de cannabinoides hydrosolubles comprenant une enzyme Download PDF

Info

Publication number
CA3044735C
CA3044735C CA3044735A CA3044735A CA3044735C CA 3044735 C CA3044735 C CA 3044735C CA 3044735 A CA3044735 A CA 3044735A CA 3044735 A CA3044735 A CA 3044735A CA 3044735 C CA3044735 C CA 3044735C
Authority
CA
Canada
Prior art keywords
formulation
acid
lipase
detergent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3044735A
Other languages
English (en)
Other versions
CA3044735A1 (fr
Inventor
Pankaj Modi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA3044735A priority Critical patent/CA3044735C/fr
Publication of CA3044735A1 publication Critical patent/CA3044735A1/fr
Application granted granted Critical
Publication of CA3044735C publication Critical patent/CA3044735C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une formulation pour solubiliser un agent pharmaceutique insoluble dans leau est décrite. La formulation comprend : un agent pharmaceutique insoluble dans leau, un détergent, une enzyme qui décompose les lipides, les protéines et/ou les amidons, un agent plastifiant, un agent émulsifiant et un solvant aqueux. Un procédé de fabrication de la formulation est également décrite.
CA3044735A 2019-05-30 2019-05-30 Formations de cannabinoides hydrosolubles comprenant une enzyme Active CA3044735C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3044735A CA3044735C (fr) 2019-05-30 2019-05-30 Formations de cannabinoides hydrosolubles comprenant une enzyme

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA3044735A CA3044735C (fr) 2019-05-30 2019-05-30 Formations de cannabinoides hydrosolubles comprenant une enzyme

Publications (2)

Publication Number Publication Date
CA3044735A1 CA3044735A1 (fr) 2019-08-07
CA3044735C true CA3044735C (fr) 2021-01-19

Family

ID=67542473

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3044735A Active CA3044735C (fr) 2019-05-30 2019-05-30 Formations de cannabinoides hydrosolubles comprenant une enzyme

Country Status (1)

Country Link
CA (1) CA3044735C (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114073671B (zh) * 2020-08-14 2022-12-20 中国科学院化学研究所 一种大麻二酚水溶性组合物、制剂及其制备方法和应用
US20230219015A1 (en) * 2020-08-26 2023-07-13 K.D. Pharma Bexbach Gmbh Extraction method and mixture of substances
LU102018B1 (de) * 2020-08-26 2022-02-28 K D Pharma Bexbach Gmbh Extraktionsverfahren und Stoffgemisch
CA3227884A1 (fr) 2021-08-04 2023-02-09 John Crawford Derives cannabinoides et leur utilisation

Also Published As

Publication number Publication date
CA3044735A1 (fr) 2019-08-07

Similar Documents

Publication Publication Date Title
US11298336B2 (en) Water soluble formulation
CA3044735C (fr) Formations de cannabinoides hydrosolubles comprenant une enzyme
AU2020257071B2 (en) Novel orally adminstrable formulation
EP0215635B1 (fr) Capsules à mâcher
AU2016238337B2 (en) Liquisoft capsules
US11166912B2 (en) Orally administrable composition
EP2961377B1 (fr) Stabilité ameliorée de nouvelles compositions liquides
US20080014274A1 (en) Enhanced stability phenylephrine liquid compositions
HU227452B1 (en) Mucoadhesive pharmaceutical formulation
EA027150B1 (ru) Пероральная фармацевтическая композиция, ее применение в медицине и способ лечения путем ее введения
US20250360176A1 (en) Chewing gum containing synergistic medicinal compounds
US11786475B2 (en) Film-based dosage form
JP2006515603A (ja) 粉末医薬組成物
US20130251808A1 (en) Pharmaceutical composition, method of preparation and methods of treating aches/pains
AU2003222437A1 (en) Pharmaceutical formulation in a drug delivery system and process for preparing the same
WO2016084099A1 (fr) Composition de capsule en gélatine souple d'agents antitussifs
EP0228223A2 (fr) Solution non irritante à base de suprofène
CA3175841A1 (fr) Formulations naturellement derivees, a administration orale, contenant des emulsions de phytocannabinoide
US20220226240A1 (en) Orally administrable composition
CA3219573A1 (fr) Formulation administree oralement
MX2007010163A (es) Composicion farmaceutica liquida acuosa estable a temperatura ambiente.
US20160166694A1 (en) Pharmaceutical composition, method of preparation and methods of treating aches/pains
WO2005032516A1 (fr) Formulation et procede de fabrication de capsules d'aceclofenac auto-microemulsionne
CN114558042A (zh) 藏青果植物的提取物及其应用
RS53364B (sr) Stabilna tečna farmaceutska formulacija

Legal Events

Date Code Title Description
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250526

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250526